Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,778 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the sale, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Simon Read also recently made the following trade(s):

• On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $109.55, for a total value of $304,220.35.

Dianthus Therapeutics Trading Down 3.7%

Shares of DNTH opened at $109.51 on Friday. The firm has a market cap of $5.99 billion, a P/E ratio of -26.39 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12-month low of $22.76 and a 12-month high of $117.88. The company’s 50-day moving average price is $100.17 and its 200 day moving average price is $84.80.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DNTH. Alyeska Investment Group L.P. increased its stake in shares of Dianthus Therapeutics by 188.2% during the second quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company’s stock worth $14,680,000 after acquiring an additional 98,345 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Dianthus Therapeutics by 24.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,396 shares of the company’s stock valued at $7,350,000 after purchasing an additional 14,961 shares during the period. Wellington Management Group LLP lifted its position in Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $574,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $207,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wedbush upped their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.